Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nature-inspired Novel Drug Design Paradigm Using Nanosilver: Efficacy on Multi-Drug-Resistant Clinical Isolates of Tuberculosis

Nature-inspired Novel Drug Design Paradigm Using Nanosilver: Efficacy on Multi-Drug-Resistant... Despite discovery of the pathogen more than 100 years ago, tuberculosis (TB) continues to be a major killer disease worldwide. Currently a third of world population is infected and multiple-drug-resistant (mdr) TB registers maximum mortality by a single pathogen. Nanomedicine provides enormous opportunity for developing novel drugs. We have recently demonstrated surface-modified-lipophilic-nanosilica as drug to combat malaria and 100% lethal virus, BmNPV. Nanosilver possesses inherent antibacterial properties, but toxicity is a major concern. We hypothesized that capping with nature-inspired biomolecules, bovine serum albumin (BSA) and Poly-n-vinyl-pyrrolidone (PVP) used as blood volume extender, might insure biosafety. BSA-nano-Ag was found to be more stable than PVP-nano-Ag at physiological pH. In this first ever study on clinical isolates collected from TB endemic areas, we report, BSA-nano-Ag act as potent anti-TB drug. Further study with (human serum albumin)-nano-Ag and core–shell-nano-Ag could increase the biocompatibility of oral TB drug formulations without compromising on the efficacy of the drug. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Microbiology Springer Journals

Nature-inspired Novel Drug Design Paradigm Using Nanosilver: Efficacy on Multi-Drug-Resistant Clinical Isolates of Tuberculosis

Loading next page...
 
/lp/springer-journals/nature-inspired-novel-drug-design-paradigm-using-nanosilver-efficacy-FDKPhjZKpJ

References (24)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer Science+Business Media, LLC
Subject
Life Sciences; Biotechnology; Microbiology
ISSN
0343-8651
eISSN
1432-0991
DOI
10.1007/s00284-010-9770-7
pmid
20936471
Publisher site
See Article on Publisher Site

Abstract

Despite discovery of the pathogen more than 100 years ago, tuberculosis (TB) continues to be a major killer disease worldwide. Currently a third of world population is infected and multiple-drug-resistant (mdr) TB registers maximum mortality by a single pathogen. Nanomedicine provides enormous opportunity for developing novel drugs. We have recently demonstrated surface-modified-lipophilic-nanosilica as drug to combat malaria and 100% lethal virus, BmNPV. Nanosilver possesses inherent antibacterial properties, but toxicity is a major concern. We hypothesized that capping with nature-inspired biomolecules, bovine serum albumin (BSA) and Poly-n-vinyl-pyrrolidone (PVP) used as blood volume extender, might insure biosafety. BSA-nano-Ag was found to be more stable than PVP-nano-Ag at physiological pH. In this first ever study on clinical isolates collected from TB endemic areas, we report, BSA-nano-Ag act as potent anti-TB drug. Further study with (human serum albumin)-nano-Ag and core–shell-nano-Ag could increase the biocompatibility of oral TB drug formulations without compromising on the efficacy of the drug.

Journal

Current MicrobiologySpringer Journals

Published: Oct 10, 2010

There are no references for this article.